Genesis Therapeutics logo

Genesis Therapeutics

Challenger

Genesis Therapeutics (now Genesis Molecular AI) is a biotech company applying AI to small molecule drug discovery; raised $200M Series B in 2025 led by Andreessen Horowitz, Fidelity, BlackRock, and NVIDIA;

Best for: AI-Driven Small Molecule Drug Discovery
Life Sciences & BioTechAI-Driven Small Molecule Drug DiscoveryWebsiteUpdated May 2026

Company Overview

About Genesis Therapeutics

Genesis Therapeutics — now operating as Genesis Molecular AI — is a clinical-stage biotechnology company founded in 2019 and headquartered in Burlingame, California. The company applies artificial intelligence and machine learning to the discovery and optimization of small molecule drug candidates, with a focus on targets that have historically been considered intractable or undruggable by conventional computational chemistry approaches. Its proprietary platform, GEMS (Genesis Exploration of Molecular Space), uses deep learning to navigate the vast chemical space of possible drug-like molecules, identifying novel compounds with high predicted potency, selectivity, and drug-like properties against disease-relevant protein targets.

Business Model & Competitive Advantage

In 2025, Genesis raised $200 million in a Series B round led by Andreessen Horowitz, with participation from Fidelity Management, BlackRock, and NVIDIA''s venture capital arm — a syndicate that reflects both the biotech and AI technology investor communities. The round brought Genesis''s total funding to over $300 million. The company also announced strategic research collaborations totaling over $65 million in upfront payments with Gilead Sciences and Incyte Corporation, validating its platform in the eyes of large pharmaceutical partners.

Competitive Landscape 2025–2026

Genesis Therapeutics differentiates from other AI drug discovery companies by combining deep molecular AI with in-house chemistry and biology capabilities — enabling it to advance programs from computational hit identification through lead optimization and into IND-enabling studies without depending entirely on CRO partners. The company is building an internal pipeline of drug candidates while simultaneously pursuing pharma partnerships that provide near-term revenue and scientific validation. It competes with Recursion Pharmaceuticals, Schrödinger, Relay Therapeutics, and Insilico Medicine in the rapidly growing AI drug discovery sector, where capital deployment has increased substantially as investors bet on AI''s ability to compress drug development timelines and costs.

Founded
2019
Headquarters
Burlingame, California
Curated content • Fact-checked and verified

Key Differentiators

Strong Challenger

Genesis Therapeutics is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.

Frequently Asked Questions

Similar Brands

Numerion Labs logo

Numerion Labs

Life Sciences & BioTech
B2bAi PoweredSaasPlatformNorth AmericaHealthtechStartup

Numerion Labs, formerly known as Atomwise, is an AI-driven drug discovery company that uses deep learning to accelerate the identification of small molecule drug candidates. The company''s core techno

Neuralink logo

Neuralink

Life Sciences & BioTech
HealthtechHardwareAi PoweredB2b2cStartupDecacornNorth AmericaTechnologyPlatformEnterprise

Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa

Illumina logo

Illumina

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechAnalyticsHardwarePlatformFortune500

Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat

BioNTech logo

BioNTech

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechManufacturingPlatform

BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere

Pliant Therapeutics logo

Pliant Therapeutics

BioTech
HealthtechTechnologyPublicB2bStartup

Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero

Cradle logo

Cradle

Life Sciences & BioTech
HealthtechSaasNorth AmericaB2b

Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti

For Genesis Therapeutics

Claim This Profile

Are you from Genesis Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Genesis Therapeutics Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Genesis Therapeutics vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →